Gain Therapeutics Inc (GANX) Stock Price, Quote & News

Company Profile

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead drug candidate is GT-02287, which is currently in...

Industry: Biotechnology

Sector: Healthcare

Phone: 301 500 1556

Website: gaintherapeutics.com

Address:

4800 Montgomery Lane, Suite 220, Bethesda, United States

chipthehampster Aug. 24 at 9:33 PM

$GANX wonder which one of these wants to add another 6 to 8 billion to their revenues

2 · Reply

GordonGeiko Aug. 24 at 8:10 PM

$GANX this stock’s day will come but man the opportunity cost has been a killer

2 · Reply

MQuick Aug. 24 at 7:53 PM

$GANX ok maybe we dont lift today 😜

0 · Reply

capnkirk606 Aug. 24 at 7:50 PM

$GANX Did some quick AI-aided research and traditionally PD requires 2 phase 3 studies. However if we get BTD and FTD (breakthrough and fast track) designations, there’s a possibility for a phase 2 trial to be registrational (no more trials needed). That would be fantastic right?! But the phase 2 would have to be very robust and designed with input from the FDA. Since we’re coming up on the start of phase 2 and the whole partnership/buyout question still seems to be ongoing/unannounced, I was wondering if this is a viable path for Gain. Don’t know much about how this stuff works tbh, maybe someone here does.

1 · Reply

john_Ennis Aug. 24 at 6:25 PM

$GANX i can't see us being pulled down to 2 again at the end of this month.

1 · Reply

john_Ennis Aug. 24 at 6:23 PM

$GANX we have the intention of starting a phase 2 this quarter but its not set in stone. If a tricky buyout negotiation means that they need another month i wont complain. If it ultimately leeds to better value.

1 · Reply

john_Ennis Aug. 24 at 6:19 PM

$GANX 2.01 Maybe news is leaking out.

1 · Reply

MQuick Aug. 24 at 5:40 PM

$GANX ok we lift by end of day mms still covering on low volume

1 · Reply

MQuick Aug. 24 at 4:22 PM

$GANX we lift in next hour

0 · Reply

Droppinscrews Aug. 24 at 4:20 PM

$GANX are we expecting either a partnership or secondary by end of Q3? A secondary offering of 10m @ 1.80 and 5m warrants @ .5 per share with a $2.25 exercise price wouldn’t be so bad. It would give them $18M for p2 and outstanding shares would only be around 56m. Share price would bounce back fast with cash runway overhang no longer in question

2 · Reply

Gain Therapeutics Earnings release: Q2 2026

Aug 11, 2026, 4:00 PM EDT - 13 days ago

Gain Therapeutics Quarterly report: Q2 2026

2026-08-11T11:20:32.000Z - 13 days ago

Gain Therapeutics reports Q2 EPS (11c), consensus (15c)

Aug 3, 2026, 7:00 AM EDT - 21 days ago

Gain Therapeutics Slides: Corporate presentation

Jul 16, 2026, 7:00 AM EDT - 5 weeks ago

Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update

2026-06-29T20:20:50.000Z - 2 months ago

Gain Therapeutics receives FDA clearance of GT-02287 IND application

Jun 29, 2026, 4:05 PM EDT - 2 months ago

Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson's Disease

Jun 15, 2026, 7:00 AM EDT - 2 months ago

Gain Therapeutics Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference

Jun 10, 2026, 7:00 AM EDT - 2 months ago

Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit

Jun 9, 2026, 7:00 AM EDT - 2 months ago

Gain Therapeutics Slides: Corporate presentation

2026-05-26T14:58:26.000Z - 3 months ago

Gain Therapeutics presents data from Phase 1b study of GT-02287

May 26, 2026, 8:00 AM EDT - 3 months ago

Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026

2026-05-12T19:29:06.000Z - 3 months ago

Gain Therapeutics price target lowered to $8 from $10 at Roth Capital

May 11, 2026, 4:00 PM EDT - 3 months ago

Gain Therapeutics Earnings release: Q1 2026

May 11, 2026, 4:00 PM EDT - 3 months ago

Gain Therapeutics Quarterly report: Q1 2026

2026-05-11T11:47:50.000Z - 3 months ago

Gain Therapeutics reports Q1 EPS (13c), consensus (14c)

May 11, 2026, 7:00 AM EDT - 3 months ago

Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update

May 5, 2026, 7:00 AM EDT - 3 months ago

Gain Therapeutics Slides: Corporate presentation

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Gain Therapeutics Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Gain Therapeutics Proxy statement: Proxy filing

Apr 24, 2026, 8:30 AM EDT - 4 months ago

Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026

2026-04-17T16:20:14.000Z - 4 months ago

Gain Therapeutics management to meet with Maxim

Apr 8, 2026, 7:00 AM EDT - 4 months ago

Gain Therapeutics Slides: Corporate presentation

Mar 26, 2026, 4:00 PM EDT - 5 months ago

Gain Therapeutics Annual report: Q4 2025

Mar 26, 2026, 4:00 PM EDT - 5 months ago

Gain Therapeutics Earnings release: Q4 2025

2026-03-26T11:26:07.000Z - 5 months ago

Gain Therapeutics reports Q4 EPS (61c), consensus (14c)

Mar 26, 2026, 7:00 AM EDT - 5 months ago

Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update

Mar 24, 2026, 1:30 PM EDT - 5 months ago

Gain Therapeutics Transcript: The 38th Annual Roth Conference

Mar 19, 2026, 4:57 PM EDT - 5 months ago

Gain Therapeutics to Present at the 38th Annual ROTH Conference

2026-03-18T12:38:06.000Z - 5 months ago

Gain announces presentations on Phase 1b clinical study of GT-02287

Mar 18, 2026, 8:15 AM EDT - 5 months ago

Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026

2026-03-12T11:32:59.000Z - 5 months ago

Gain Therapeutics provides regulatory update on GT-02287

Mar 12, 2026, 7:00 AM EDT - 5 months ago

Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update

Mar 8, 2026, 7:00 AM EDT - 6 months ago

Gain Therapeutics Slides: Corporate presentation

Feb 19, 2026, 7:00 AM EST - 6 months ago

Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

Jan 7, 2026, 7:00 AM EST - 8 months ago

Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week

Jan 6, 2026, 10:00 AM EST - 8 months ago

Gain Therapeutics Transcript: Study Update

Jan 6, 2026, 10:00 AM EST - 8 months ago

Gain Therapeutics Press release: Study Update

2026-01-06T12:26:07.000Z - 8 months ago

Gain Therapeutics provides additional data from Phase 1b study of GT-02287

Jan 6, 2026, 7:00 AM EST - 8 months ago

Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287

2025-12-30T16:00:13.000Z - 8 months ago

Gain Therapeutics holds a conference call

2025-12-19T18:35:13.000Z - 8 months ago

Gain Therapeutics price target raised to $10 from $6 at Roth Capital

Dec 18, 2025, 4:05 PM EST - 8 months ago

Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease

2025-12-18T12:10:20.000Z - 8 months ago

Gain Therapeutic announces Phase 1b study of GT-02287 met prespecified endpoint

Dec 18, 2025, 7:00 AM EST - 8 months ago

Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson's Disease

2025-11-20T12:05:27.000Z - 9 months ago

Gain Therapeutics presents data on GT-02287

Nov 20, 2025, 7:00 AM EST - 9 months ago

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025

2025-11-12T12:15:51.000Z - 10 months ago

Gain Therapeutics reports Q3 EPS (15c), consensus (15c)

Nov 12, 2025, 7:00 AM EST - 10 months ago

Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update

Nov 12, 2025, 7:00 AM EST - 10 months ago

Gain Therapeutics Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 10 months ago

Gain Therapeutics Quarterly report: Q3 2025

Nov 7, 2025, 7:00 AM EST - 10 months ago

Gain Therapeutics Registration statement: Registration Filing

Oct 30, 2025, 7:00 AM EDT - 10 months ago

Gain Therapeutics to Present at Neuroscience 2025

2025-10-16T11:45:35.000Z - 11 months ago

Gain Therapeutics price target lowered to $5 from $9 at BTIG

Oct 16, 2025, 7:00 AM EDT - 11 months ago

Gain Therapeutics to Attend the 2025 Maxim Growth Summit

Oct 14, 2025, 4:00 PM EDT - 11 months ago

Gain Therapeutics Transcript: Study Result

2025-10-07T13:10:58.000Z - 11 months ago

Gain Therapeutics price target raised to $7 from $5 at Maxim

Oct 6, 2025, 8:15 AM EDT - 11 months ago

Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson's Patients at International Congress of Parkinson's Disease and Movement Disorders®

Sep 23, 2025, 7:40 AM EDT - 11 months ago

Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025

Sep 18, 2025, 7:41 AM EDT - 1 year ago

Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson's Disease

Sep 4, 2025, 8:00 AM EDT - 1 year ago

Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation

Aug 12, 2025, 4:00 PM EDT - 1 year ago

Gain Therapeutics Quarterly report: Q2 2025

Aug 12, 2025, 4:00 PM EDT - 1 year ago

Gain Therapeutics Earnings release: Q2 2025

Aug 12, 2025, 7:00 AM EDT - 1 year ago

Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update

Jul 24, 2025, 8:53 AM EDT - 1 year ago

Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference

Jul 16, 2025, 9:03 AM EDT - 1 year ago

Gain Therapeutics Announces Pricing of $7.0 Million Public Offering

Jul 15, 2025, 4:36 PM EDT - 1 year ago

Gain Therapeutics Announces Proposed Public Offering

Jun 30, 2025, 4:05 PM EDT - 1 year ago

Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson's Disease With or Without a GBA1 Mutation

Jun 10, 2025, 8:00 AM EDT - 1 year ago

Gain Therapeutics to Participate in Upcoming Investor Conferences

May 29, 2025, 8:45 AM EDT - 1 year ago

Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting

May 28, 2025, 8:00 AM EDT - 1 year ago

Gain Therapeutics Registration statement: Registration Filing

May 14, 2025, 4:00 PM EDT - 1 year ago

Gain Therapeutics Earnings release: Q1 2025

May 14, 2025, 4:00 PM EDT - 1 year ago

Gain Therapeutics Quarterly report: Q1 2025

May 14, 2025, 7:30 AM EDT - 1 year ago

Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update

May 12, 2025, 7:30 AM EDT - 1 year ago

Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders

May 1, 2025, 7:30 AM EDT - 1 year ago

Gain Therapeutics to Participate at The Citizens Life Sciences Conference

Apr 30, 2025, 7:45 AM EDT - 1 year ago

Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Gain Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Gain Therapeutics Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Gain Therapeutics Proxy statement: Proxy Filing

Mar 28, 2025, 8:30 AM EDT - 1 year ago

Gain Therapeutics Announces Poster Presentation at AD/PD 2025

Mar 27, 2025, 1:30 PM EDT - 1 year ago

Gain Therapeutics Annual report: Q4 2024

Mar 27, 2025, 1:30 PM EDT - 1 year ago

Gain Therapeutics Earnings release: Q4 2024

Mar 27, 2025, 7:00 AM EDT - 1 year ago

Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update

Mar 14, 2025, 7:45 AM EDT - 1 year ago

Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease

Mar 6, 2025, 7:55 AM EST - 1 year ago

Gain Therapeutics Announces Oral Presentation at AD/PD 2025

Feb 6, 2025, 8:45 AM EST - 1 year ago

Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update

Feb 5, 2025, 8:30 AM EST - 1 year ago

Gain Therapeutics To Participate in Upcoming Investor Conferences

Dec 23, 2024, 7:30 AM EST - 1 year ago

Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson's Disease

Dec 11, 2024, 8:30 AM EST - 1 year ago

Gain Therapeutics To Present At Biotech Showcase 2025

Nov 14, 2024, 12:00 AM EST - 1 year ago

Gain Therapeutics Quarterly report: Q3 2024

Nov 14, 2024, 12:00 AM EST - 1 year ago

Gain Therapeutics Earnings release: Q3 2024

Oct 15, 2024, 12:00 PM EDT - 2 years ago

Gain Therapeutics Transcript: Maxim Group’s 2024 Healthcare Virtual Summit

Oct 7, 2024, 7:00 AM EDT - 2 years ago

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024

Oct 3, 2024, 7:00 AM EDT - 2 years ago

Gain Therapeutics to Participate at Upcoming Investor Conferences

Sep 30, 2024, 7:00 AM EDT - 2 years ago

Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson's Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers

Sep 26, 2024, 7:00 AM EDT - 2 years ago

Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease

Sep 19, 2024, 7:00 AM EDT - 2 years ago

Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson's Disease Models Including Two Late-Breakers at Neuroscience 2024

Aug 29, 2024, 7:30 AM EDT - 2 years ago

Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease

Aug 8, 2024, 4:00 PM EDT - 2 years ago

Gain Therapeutics Quarterly report: Q2 2024

Aug 8, 2024, 4:00 PM EDT - 2 years ago

Gain Therapeutics Earnings release: Q2 2024

Aug 8, 2024, 7:30 AM EDT - 2 years ago

Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update

Jul 9, 2024, 7:00 AM EDT - 2 years ago

Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson's Disease

chipthehampster Aug. 24 at 9:33 PM

$GANX wonder which one of these wants to add another 6 to 8 billion to their revenues

2 · Reply

GordonGeiko Aug. 24 at 8:10 PM

$GANX this stock’s day will come but man the opportunity cost has been a killer

2 · Reply

MQuick Aug. 24 at 7:53 PM

$GANX ok maybe we dont lift today 😜

0 · Reply

capnkirk606 Aug. 24 at 7:50 PM

1 · Reply

john_Ennis Aug. 24 at 6:25 PM

$GANX i can't see us being pulled down to 2 again at the end of this month.

1 · Reply

john_Ennis Aug. 24 at 6:23 PM

1 · Reply

john_Ennis Aug. 24 at 6:19 PM

$GANX 2.01 Maybe news is leaking out.

1 · Reply

MQuick Aug. 24 at 5:40 PM

$GANX ok we lift by end of day mms still covering on low volume

1 · Reply

MQuick Aug. 24 at 4:22 PM

$GANX we lift in next hour

0 · Reply

Droppinscrews Aug. 24 at 4:20 PM

2 · Reply

USAEquityResearch Aug. 24 at 4:02 PM

$GANX 📊 USAEquityResearch ▼ 1.98 (-1.25%) Trend: Bullish 📈 RSI (14): 62.8 — strong momentum, approaching overbought MACD: bullish, above signal line and rising Volume: below average 📌 Key Levels Resistance: 2.16 | Support: 1.68 20-MA: 1.91 | 50-MA: 1.84 💼 Fundamentals Mkt Cap: $86.41M FCF: $-11.14M (-0.26/sh) Total Debt: $609,874 D/E: 5.4 📉 Options (exp 2026-09-18) ATM IV: 94.5% | Skew: -81.2% (call-heavy) P/C Ratio: 0.05 🐂 Bullish lean Max Pain: 1.00 Call wall: 2.00 | Put wall: 1.00 Educational content only. Not financial advice. Full data, options chain & financials: https://usaequityresearch.com/stocks/GANX

0 · Reply

MQuick Aug. 24 at 2:44 PM

$GANX they are covering their $2 deliveries then we rise

0 · Reply

john_Ennis Aug. 24 at 2:43 PM

$GANX even Nvidia is down 2 percent. Don't tell me Data centers are out of fashion

0 · Reply

MQuick Aug. 24 at 2:19 PM

$GANX covering all they can below $2 because they dont lose

0 · Reply

Bach_A Aug. 24 at 2:06 PM

$GANX whole market is on sale today guys chill lol

0 · Reply

Jeffreyb7173 Aug. 24 at 2:02 PM

$GANX let me see if I understand… - patent cliff is here - BP’s all looking for the next big drug - neurodegenerative diseases in focus - drug discovery platforms hot But here we sit. Cmon gene and Khalid, work some magic… this is getting ridiculous

1 · Reply

R_Mansfield Aug. 24 at 1:56 PM

$GANX It's back to $1.70 before too long.

0 · Reply

Rschmidt61 Aug. 24 at 1:43 PM

$GANX more opportunities to buy here . In deep already anyway

0 · Reply

Thebullsafool Aug. 24 at 1:39 PM

$GANX

0 · Reply

MQuick Aug. 24 at 1:39 PM

$GANX stock close $2.25-$2.30 IMO

0 · Reply

MQuick Aug. 24 at 1:35 PM

$GANX now theyve got to cover 200k they had to deliver

0 · Reply

microcapspeculator Aug. 24 at 1:31 PM

$GANX Maybe we can cure cancer with GT-02287. Explains why it's mentioned as a target in the patents. Blocking glucosylceramide production kills cancer cells via lysosomal https://bioengineer.org/blocking-glucosylceramide-production-kills-cancer-cells-via-lysosomal-dysfunction-not-ceramide-buildup/

0 · Reply

Market Cap	87.51M
Revenue (ttm)	0.00
Net Income (ttm)	-20.16M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.03

Volume	302,400
Avg Vol	880,462
Day's Range	N/A - N/A
Shares Out	43.64M
Stochastic %K	38%
Beta	0.19
Analysts	Strong Sell
Price Target	$7.20